Oral agents for the treatment of premature ejaculation: Review of efficacy and safety in the context of the recent international society for sexual medicine criteria for lifelong premature ejaculation

Journal of Sexual Medicine

Volumn 8, Issue 10, 2011, Pages 2707-2725

  Mcmahon, Chris G ^a   Porst, Hartmut ^b  

^a Australian Centre for Sexual Health   (Australia)

^b Private Urology and Andrology Practice and Hospital   (Germany)

Author keywords

Bother; Control over ejaculation; Distress; IELT; ISSM criteria; Premature ejaculation

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ALFUZOSIN; CITALOPRAM; CLOMIPRAMINE; DAPOXETINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TADALAFIL; TERAZOSIN; TRAMADOL; VARDENAFIL;

ABNORMAL SENSATION; AGITATION; AKATHISIA; ANXIETY DISORDER; ARABIC INDEX OF PREMATURE EJACULATION; ASTHENIA; BEHAVIOR CHANGE; CHILL; CHINESE INDEX OF PREMATURE EJACULATION; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION; EVIDENCE BASED MEDICINE; FACE DISORDER; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPOMANIA; IMPOTENCE; IMPULSIVENESS; INDEX OF PREMATURE EJACULATION; INSOMNIA; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTRAVAGINAL EJACULATORY LATENCY TIME; IRRITABILITY; LIBIDO DISORDER; MUSCLE DISEASE; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); PREMATURE EJACULATION; PREMATURE EJACULATION PROFILE; PREMATURE EJACULATION QUESTIONNAIRE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RHINOPHARYNGITIS; SEXUAL SATISFACTION; SIDE EFFECT; SKIN REDNESS; SOMNOLENCE; SUICIDAL IDEATION; SYNCOPE; SYSTEMATIC REVIEW (TOPIC); UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; YAWNING; YONSEI SEXUAL FUNCTION INVENTORY;

EID: 80053576310     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02386.x     Document Type: Article

References (69)

1. Shindel A, Nelson C, Brandes S. Urologist practice patterns in the management of premature ejaculation: A nationwide survey. J Sex Med 2008;5:199-205.
2. Sadeghi-Nejad H, Watson R. Premature ejaculation: Current medical treatment and new directions (CME). J Sex Med 2008;5:1037-50.
3. Bettocchi C, Verze P, Palumbo F, Arcaniolo D, Mirone V. Ejaculatory disorders: Pathophysiology and management. Nat Clin Pract Urol 2008;5:93-103.
4. Althof SE, Levine SB, Corty EW, Risen CB, Stern EB, Kurit DM. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 1995;56:402-7.
5. Palmer NR, Stuckey BG. Premature ejaculation: A clinical update. Med J Aust 2008;188:662-6.
6. Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol 1995;28:126-30.
7. Basar MM, Yilmaz E, Ferhat M, Basar H, Batislam E. Terazosin in the treatment of premature ejaculation: A short-term follow-up. Int Urol Nephrol 2005;37:773-7.
8. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med 2008;5:188-93.
9. Alghobary M, El-Bayoumy Y, Mostafa Y, Mahmoud EH, Amr M. Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation. J Sex Med 2010;7:2860-7.
10. Gurkan L, Oommen M, Hellstrom WJ. Premature ejaculation: Current and future treatments. Asian J Androl 2008;10:102-9.
11. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S, Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation: Integrated analysis of two randomized, double-blind, placebo-controlled trials. Lancet 2006;368:929-37.
12. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009;55:957-68.
13. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: Results from a placebo-controlled phase III trial. BJU Int 2009;103:651-8.
14. McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, Rothman M, Aquilina J, Dapoxetine 3003 Study Investigators. Treatment of premature ejaculation in the Asia-Pacific region: Results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010;7:256-68.
15. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip I, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJ, Incrocci L, Laan E, Meuleman E, Perelman MA, Rosen R, Rowland D, Segraves R, International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med 2008;5:1590-606.
16. McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies-part II-study design, outcome measures, data analysis, and reporting. J Sex Med 2008;5:1817-33.
17. Porst H, Vardi Y, Akkus E, Melman A, Park NC, Seftel AD, Teloken C, Wyllie M. Standards for clinical trials in male sexual dysfunctions. J Sex Med 2010;7:414-44.
18. McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies-Part I-Defining and selecting the study population. J Sex Med 2008;5:1805-16.
19. Waldinger MD, Zwindermann AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: A systematic review and meta-analysis. Int J Impot Res 2004;16:369-81.
20. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review. BJU Int 2006;98:259-72.
21. Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, Spera G. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 2009;21:221-7.
22. Novaretti JPT, Pompeo ACL, Arap S. Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. Braz J Urol 2002;28:116-22.
23. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: Prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008;80:162-5.
24. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study. J Urol 1996;156:1631-2.
25. Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 2007;39:115-8.
26. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: A placebo-controlled study. Int J Impot Res 2002;14:502-5.
27. McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, Haughie S, Boolell M. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005;2:368-75.
28. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998;18:274-81.
29. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: A double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001;21:293-7.
30. US Food and Drug Administration (FDA). US FDA draft guidance for industry, patient reported outcome measures: Use in medical product development to support labeling claims. December 2009. Available at: (accessed June 24 2011).
31. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JM, Tesfaye F, Rothman M, Rivas DA, Porst H. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: Integrated analysis of results from five phase 3 trials. J Sex Med 2011;8:524-39.
32. Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L. Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 2006;3:465-75.
33. Hartmann U. The "PEQUEST": A multidimensional instrument for the assessment of premature ejaculation. Int J Impot Res 1996;8:119.
34. Yuan YM, Xin ZC, Jiang H, Guo YJ, Liu WJ, Tian L, Zhu JC Sexual function of premature ejaculation patients assayed with Chinese Index of Premature Ejaculation. Asian J Androl 2004;6:121-6.
35. Arafa M, Shamloul R. Development and evaluation of the Arabic Index of Premature Ejaculation (AIPE). J Sex Med 2007;4:1750-6.
36. Rosen RC, McMahon CG, Niederberger C, Broderick GA, Jamieson C, Gagnon DD. Correlates to the clinical diagnosis of premature ejaculation: Results from a large observational study of men and their partners. J Urol 2007;177:1059-64.
37. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, McNulty P, Rothman M, Jamieson C. Premature ejaculation: An observational study of men and their partners. J Sex Med 2005;2:358-67.
38. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
39. Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002;14:226-44.
40. Lee HS, Song DH, Kim CH, Choi HK. An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol 1996;16:379-82.
41. Waldinger MD. Towards evidence-based drug treatment research on premature ejaculation: A critical evaluation of methodology. Int J Impot Res 2003;15:309-13.
42. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: A critical analysis of basic science and clinical data. Eur Urol 2007;52:1331-9.
43. Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, Rosen RC, Sadovsky R, Waldinger M, Becher E, Broderick GA, Buvat J, Goldstein I, El-Meliegy AI, Giuliano F, Hellstrom WJ, Incrocci L, Jannini EA, Park K, Parish S, Porst H, Rowland D, Segraves R, Sharlip I, Simonelli C, Tan HM; International Society for Sexual Medicine. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010;7:2947-69.
44. Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, Waldinger MD, Ahn Ty. Disorders of orgasm and ejaculation in men. J Sex Med 2010;7:1668-86.
45. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile: Validation of self-reported outcome measures for research and practice. BJU Int 2009;103:358-64.
46. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aguilina JW, Tesfaye F, Rivas DA. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: Integrated analyses of two phase 3 dapoxetine trials. J Sex Med 2010;7:2231-42.
47. Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002;168:2486-9.
48. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. The majority of men with lifelong premature ejaculation prefer daily drug treatment: An observation study in a consecutive group of Dutch men. J Sex Med 2007;4:1028-37.
49. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825-37.
50. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
51. Markowitz JS, DeVane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000;15:329-33.
52. Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomised trials: Systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005;5:18.
53. Hytrin. Hytrin (terazosin hcl tablets) [package insert]. North Chicago, IL: Abbott Laboratories; 2006, 2008.
54. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: A systematic review and metaanalysis. J Rheumatol 2007;34:543-55.
55. Cossmann M, Kohnen C, Langford R, McCartney C. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance]. Drugs 1997;53(suppl 2):50-62.
56. McDiarmid T, Mackler L, Schneider DM. Clinical inquiries. What is the addiction risk associated with tramadol? J Fam Pract 2005;54:72-3.
57. Adams EH, Breiner S, Cicero TJ, Geller A, Inciardi JA, Schnoll SH, Senay EC, Woody GE. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006;31:465-76.
58. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
59. Montague DK, Jarow J, Broderick G, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID; AUA Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004;172:290-4.
60. McMahon CG, Abdo C, Incrocci L, Perelman M, Rowland D, Waldinger M, Xin ZC. Disorders of orgasm and ejaculation in men. J Sex Med 2004;1:58-65.
61. MedDra. MedDRA-Medical Dictionary for Regulatory Activities (Ver 10.1). 2008. Available at: (accessed October 22, 2008).
62. Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol 1998;13(suppl 6):S9-14.
63. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: The involvement of the serotonergic system. Behav Brain Res 1998;92:111-8.
64. McMahon CG, Samali R. Pharmacological treatment of premature ejaculation. Curr Opin Urol 1999;9:553-61.
65. Waldinger MD, Schweitzer DH, Olivier B. On-demand SSRI treatment of premature ejaculation: Pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med 2005;2:121-31.
66. PAXIL r (paroxetine hydrochloride) Tablets and Oral Suspension [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007, 2007.
67. ZOLOFT r (sertraline hydrochloride) Tablets and Oral Concentrate [package insert]. New York: Pfizer Inc; 2005, 2005.
68. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006;46:301-9.
69. Jannini EA. Editorial comment on: Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009;55:967-8.